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There have been exhaustive efforts to develop an efficient vaccine against leishmaniasis. 
Factors like host and parasite genetic characteristics, virulence, epidemiological sce-
narios, and, mainly, diverse immune responses triggered by Leishmania species make 
the achievement of this aim a complex task. It is already clear that the induction of a 
Th1, pro-inflammatory response, is important in the protection against Leishmania infec-
tion. However, many questions must still be answered to fully understand Leishmania 
immunopathology, especially regarding Leishmania-specific Th1 response induction,
regulation, and persistence. A large number of Leishmania antigens able to induce
pro-inflammatory response have been selected so far, but none of them demonstrated 
efficiency in protection assays. A possible explanation is that CD4 T cells display marked 
heterogeneity at a single-cell level especially regarding the production of Th1-defining 
cytokines and multifunctionality. It has been established in the literature that Th1 cells 
undergo a differentiation process, which can generate cells with diverse phenotypes 
and survival capabilities. Despite that, only a few studies evaluate this heterogenic
response and the amount of multifunctional CD4 T cells induced by Leishmania vaccine 
candidates, missing what can be a crucial point in defining a correlate of protection after 
vaccination. Moreover, most of the knowledge involving the development of cutaneous 
leishmaniasis (CL) vaccines comes from the mouse model of infection with Leishmania 
major, which cannot be fully applied to New World Leishmaniasis. For this reason, the 
immune response triggered by infection with New World Leishmania species, as well as 
vaccine candidates, need further studies. In this review, we will reinforce the importance 
of evaluating the quality of immune response against Leishmania, using a multiparametric 
analysis in order to understand better this complex host-parasite interaction, discussing 
the differences in the responses triggered by different New World Leishmania species, as 
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iNTRODUCTiON
World Health Organization (WHO) has classified Leishmaniasis among the tropical neglected, 
emerging, and uncontrolled diseases that affect mainly poor regions around the Globe. The disease 
is endemic in 88 countries (72 are developing countries) with approximately 350 million individuals 
at risk of contracting the disease and an annual incidence of 1.5–2 million new cases (1). Its preven-
tion has been based on control of vectors and animal reservoirs in countries where the disease has a 
TABLe 1 | Major human American cutaneous leishmaniasis causing 
species and their clinical manifestations.





L. braziliensis Viannia LCL ++ IFN-γ+++, 
IL-10++
Disseminated CL +++ IFN-γ+, IL-10++
ML ++++ IFN-γ++++, 
IL-10+
L. guyanensis Viannia LCL ++ IFN-γ++, IL-10++
L. panamensis Viannia LCL ++ IFN-γ++, IL-10++
ML ++++ IFN-γ++++, 
IL-10+
L. amazonensis Leishmania LCL ± IFN-γ+, IL-10+
Borderline CL − IFN-γ++, IL-10++
DCL − IFN-γ±, 
IL-10++++
L. mexicana Leishmania LCL ± IFN-γ++, IL-10++
DCL − IFN-γ±, 
IL-10++++
LCL, localized cutaneous leishmaniasis; ML, mucosal leishmaniasis; DCL, diffuse 
cutaneous leishmaniaisis.
−, Absence.
+, Presence; +, low; ++, moderate; +++, high; ++++, very high.
2
De Luca and Barreto Macedo Cutaneous Leishmaniasis and Vaccines
Frontiers in Immunology | www.frontiersin.org April 2016 | Volume 7 | Article 151
zoonotic transmission, combined with chemotherapy of infected 
individuals where the disease possesses anthroponotic features. 
However, control of reservoir hosts and vectors is difficult due to 
operational issues, making the development of an effective and 
affordable vaccine against Leishmaniasis a highly desirable task.
The history of Leishmania vaccination dated from twentieth 
century, in which live, virulent parasites were inoculated in 
healthy individuals in a process called “Leishmanization.” The 
practice was banned because of safety concerns due to develop-
ment of non-healing lesions and immunosuppression (2). First 
generation vaccines using whole-killed Leishmania promastig-
otes replaced Leishmanization and were tested as vaccines against 
cutaneous leishmaniasis (CL) and visceral leishmaniasis (VL) (3, 
4). Second and third generation vaccines were also developed, 
based on the defined synthetic or recombinant subunits and 
DNA, respectively. Despite many years of efforts in identifying a 
great number of antigens (5) and advances in vaccine technolo-
gies, there does not yet appear to be a vaccine candidate capable 
of delivering the level of protection needed for disease control.
The localized form of CL, specially the one caused by the Old 
World specie Leishmania major, is a self-healing disease, usually 
characterized by a state of at least partial immunity against rein-
fection, demonstrating that prevention through prophylactic vac-
cination is feasible. On the other hand, although recovery from 
infection with the New World specie Leishmania braziliensis gives 
firm resistance to homologous challenge, Leishmania amazonen-
sis infection does not provide protection against a subsequent 
challenge with L. braziliensis, or other Leishmania species from 
the subgenus Viannia (6, 7). Until now, there has been no consist-
ent data, particularly in humans, indicating that recovery from a 
primary infection with L. amazonensis gives complete resistance 
to a homologous challenge.
The fact that there is not yet an efficient vaccine against 
Leishmaniasis, especially one that could protect against dif-
ferent species simultaneously, leads us to consider that a better 
understanding of immune response in Leishmania pathogenesis 
is still needed, taking into consideration the various species that 
cause different clinical manifestations of the disease. Among 
the reasons that can be pointed out to explain our failure in 
developing a vaccine against CL, particularly against American 
cutaneous leishmaniasis, is the fact that we are still far from fully 
understand the mechanisms of healing and of memory responses 
generated after Leishmania infections as well as how to evaluate 
this responses. Far from giving the answers, this review focuses 
on the current advances in T cell memory knowledge and the dif-
ferences observed between the immune responses induced after 
infection with different Leishmania species, particularly between 
L. braziliensis and L. amazonensis.
AMeRiCAN TeGUMeNTARY 
LeiSHMANiASiS: BeYOND THe  
Th1/Th2 PARADiGM
American tegumentary leishmaniasis (ATL) is endemic in Latin 
America and the most common species involved are: L. brazilien-
sis, Leishmania guyanensis, Leishmania panamensis (all from the 
genus Viannia), L. amazonensis, and Leishmania mexicana (both 
from the subgenus Leishmania). Unlike Old World CL, usually 
characterized by subclinical or self-healing cutaneous lesions, 
the infection by ATL causing species can lead to uncontrolled 
parasite replication, producing non-healing cutaneous, mucosal, 
or even visceral disease (1) (Table 1).
Human infection with L. braziliensis leads to a broad spectrum 
of clinical, immunological, and histopathological manifestations, 
varying from self-healing cutaneous lesions to the severe and 
destructive clinical form named mucocutaneous leishmaniasis 
(ML) (8–10). The localized cutaneous form (LCL) usually mani-
fests as one or a few ulcers with elevated borders and sharp craters 
that increase rapidly in size and heal slowly without treatment 
(11). L. braziliensis can also cause disseminated leishmaniasis, in 
which up to hundreds of lesions erupt as a result of hematogenous 
spread of parasite (12, 13). L. amazonensis has also been isolated 
from patients with diverse clinical forms, such as simple CL 
lesions to diffuse cutaneous leishmaniasis (DCL) (14) and was 
also implicated in borderline disseminated CL, an intermediate 
form of disease (15). Patients with DCL are often resistant to 
chemotherapy, have negative leishmanin skin test (LST), and low 
or negative responses after Leishmania antigen-specific stimula-
tion in vitro but remain responsive for other unrelated antigens, 
such as tuberculin (8).
For many years, murine CL models have been used to eluci-
date the cell types, cytokines, signal transduction cascades, and 
mechanisms needed for parasite control and clinical resolution 
of the disease. Since Leishmania is an obligate intracellular para-
site, the protective immunity is associated with a cell-mediated 
immune response. Indeed, studies in the murine model have 
been helping to elucidate the immunological pathways that are 
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responsible for resistance or susceptibility to Leishmania and 
were responsible for the description of the CD4 T cells Th1/Th2 
dichotomy. It is well accepted that protective immunity against 
Leishmania parasites is mediated by a type 1, pro-inflammatory 
response, and most of the early studies, particularly on L. major 
infection, largely defined the Th1/Th2 paradigm of resistance/
susceptibility to infection and the role of interleukin 12 (IL-12) 
and IL-4, respectively, in driving Th1 and Th2 cell development 
(16, 17). On the other hand, in human L braziliensis infection, 
some evidences suggest that higher percentage of activated IFNγ+ 
producing T CD4+ lymphocytes are associated with larger lesions 
(18), and an exacerbated Th1 response is observed in ML (19). 
The polarized CD4 lymphocyte response detected in the murine 
L. major model is not so evident in the human Leishmanasis, and 
the importance of IL-4 as a primary mediator of susceptibility to 
Leishmania infection is not corroborated by clinical trials (19). 
Indeed, in DCL (the most severe form of human ATL), the main 
cytokine associated with immunosuppression and pathology it is 
not IL-4 but IL-10 (20–22).
The vast majority of experimental CL studies come from the 
murine model of infection with L. major, although the disease 
outcome in inbred strains of mice differs among Leishmania 
species. While C57BL/6 and C3H mice are resistant to infection 
with L. major, they develop chronic lesions when infected with 
L. amazonensis while BALB/c mice are highly susceptible to 
L. major and L. amazonensis infection, but develop self-limited 
lesions when infected with L. braziliensis (16). Little information 
has been generated in the murine model regarding ATL causing 
Leishmania species. Although some data have been published 
with L. braziliensis and L. amazonensis infection, the protocols are 
heterogeneous with respect to the stage of parasite used (station-
ary phase or metacyclic promastigotes) and the inoculation route 
(subcutaneous or intradermal), making it difficult to compare the 
results obtained (23–26).
Even though we still lack a reliable, largely accepted, and utilized 
murine model for ATL, much progress was made in understand-
ing the mechanisms involved in human pathology. However, 
many questions are still unanswered, especially those related to 
the immunological mechanisms leading to lesions healing and 
natural resistance to infection and cross-protection, as well as to 
the induction, regulation, and persistence of Leishmania-specific 
T cell response.
CD4 iMMUNe ReSPONSe AND MeMORY
The goal of vaccination is the development of immunological 
memory, classically defined as the ability of the immune system 
to respond more effectively and faster to a pathogen previously 
encountered. In the late twentieth century, memory T cells were 
divided into central memory (TCM) and effector memory cell 
(TEM) populations, based on the expression of different cell 
surface markers (27). TCM cells constitutively express CCR7 
and CD62L and are found in T cell areas of secondary lymphoid 
organs where they are able to proliferate and differentiate into 
effector cells in response to antigenic stimulation. TEM cells 
downregulate the expression of CCR7, have heterogeneous 
expression of CD62L, and are able to migrate to inflamed tissues, 
and have immediate effector functions (27, 28). One study in 
murine L. major infection demonstrated the importance of two 
populations of memory CD4 T cells in the protection against 
reinfection. While effector CD4+ T cells are lost in the absence 
of parasites, the central memory CD4+ T cells are kept and 
become tissue-homing effector T cells to mediate protection, 
suggesting that central memory T cells should be the targets 
for vaccines against Leishmania (29). The same group recently 
identified the presence of skin tissue Leishmania-specific resi-
dent memory T cells, and indicated the necessity of these cells, 
together with circulating memory T cells, for the success of a 
vaccine (30).
The induction of memory T cells was also evaluated in patients 
with CL. In patients healed form L. major infection both TEM 
IFN-γ producing cells (CD4+CD45RO+CD45RA−CCR7−) 
and Leishmania-reactive IL-2 producing TCM cells (CD4+CD
45RO+CD45RA−CCR7+) were observed after “in vitro” stimu-
lation with Leishmania soluble antigen (SLA), suggesting that 
both populations might play a role in protective recall immune 
response against reinfection (31). On the other hand, the major-
ity of L. braziliensis-healed CL and ML patients did not produce 
IFN-γ “in vitro” after SLA stimulation, but are still responsive 
“in vivo” to LST. A positive LST was found in 87.5% of CL and 
100% of ML cured individuals who did not produce IFN-γ, and 
in the individuals that maintains SLA-specific IFN-γ production, 
the main source of the cytokine was effector memory CD4+ 
T cell (32).
Usually, L. braziliensis patients healed from CL lesions should 
be monitored for approximately 5 years to rule out of the possibil-
ity of relapses or the development of metastatic mucosal lesions 
(33, 34). In one study where healed L. braziliensis CL patients were 
grouped according to the time elapsed since the end of therapy, 
a regulated leishmanial-specific response appeared to emerge 
only about 2 years after initial contact with the parasite. Ex vivo 
analyses showed a contraction for both CD4 and CD8 TEM 
compartments in patients with long-time elapsed after clinical 
cure (2–5 years). However, after “in vitro” SLA stimulation, they 
exhibit a recall response with expansion of TEM cells (35).
CD4 T cells also present different capacities to develop into 
memory cells based on their cytokine production (36), and the 
quality of a Th1 immune response has been related with a differ-
entiation spectrum based on the production of three cytokines: 
IFN-γ, IL-2, and TNF-α (37). Cells that enter this differentiation 
processes are, at first, single producers of IL-2 or double produc-
ers of IL-2/TNF-α, but are negative for IFN-γ. They can be clas-
sified as central memory cells, since are long-lasting cells able to 
respond quickly to a second antigen encounter. Te other pole of 
this spectrum is IFN-γ single-positives cells that are short-lived, 
terminal effector cells (36, 37). From one pole to the other, a 
variety of phenotypes can be found, including multifunctional 
CD4 T that are triple positives for IFN-γ, IL-2, and TNF-α (37). 
Interestingly, the amount of IFN-γ produced by multifunctional 
cells is much higher than the amount produced by double- or 
single-positive cells (38, 39). The IL-2 produced by those cells 
together with the high production of IFN-γ and TNF-α give to 
multifunctional CD4 T cells the remarkable capacity to possess 
optimal effector functions and proliferation.
TABLe 2 | Multifunctional T cells analysis on Leishmania infection and 
vaccination.
Specie Model CD4 T cell phenotype 
associated with cure or 
protection
Reference
L. major C57BL/6 IFN+TNF+IL-2+ Darrah et al. (38)
L. major C57BL/6 
and 
human
IFN+TNF+IL-2+ Darrah et al. (50)








Human IFN+TNF+IL-2+ Macedo et al. (39)
L. donovani Balb/c IFN+TNF+L-2+, IFN+TNF+, 
and IFN+IL-2+
Dey et al. (48)
L. donovani Balb/c TNF+IL-2+ and IFN+TNF+ Guha et al. (46)
L. donovani Balb/c IFN+TNF+IL-2+, 
IFN+TNF+, and IFN+IL-2+
Guha et al. (47)
L. amazonensis Balb/c TNF+IL-2+ and TNF+ Nico et al. (51)
L. major Balb/c and 
C57BL/6
IFN+TNF+IL-2+ Matos et al. (43)
L. major Human IFN+TNF+IL-2+ Lakhal-Naouar 
et al. (44)
4
De Luca and Barreto Macedo Cutaneous Leishmaniasis and Vaccines
Frontiers in Immunology | www.frontiersin.org April 2016 | Volume 7 | Article 151
CD4+ T cells not always go through each possible stage of 
differentiation and after antigen recognition, an IL-2 single-
positive cell can go straight to the IFN-γ single-positive effector 
phenotype, particularly if the stimulus is strong (36). Thus, it is 
possible that a vaccine candidate can elicit an immune response 
predominantly composed by effector cells, and fail to induce long, 
last protection against infection. A promising vaccine candidate 
should be able to induce multifunctional T cells that are able to 
proliferate and generate memory and effector cells.
In past years, the majority of studies designed to evaluate 
possible immunogens against Leishmania infection utilized 
the production of IFN-γ by antigen-specific T cells as the main 
factor to predict protection. However, it is clear that the quality 
and the magnitude of a T-cell response measured by a single 
parameter do not reflect its full functional potential which may 
be the reason why vaccines that reached phase III trials failed to 
protect against Leishmania infection (40–42). In 2007, the first 
compelling evidence for the importance of multifunctional Th1 
cells in mediating protection against Leishmaniasis revealed, 
after immunization with various vaccine formulations encod-
ing specific L. major antigens, a strong correlation between the 
generation of multifunctional CD4 T cells and the degree of pro-
tection observed after a subsequent challenge (38). Intriguingly, 
the best degree of protection and the higher percentage of multi-
functional T cells were observed in animals that healed primary 
lesions and were reinfected (“live vaccination”). Afterward, this 
approach started to be utilized by many other research groups 
to characterize immune correlates of protection after infec-
tion or after immunization against CL and VL (Table  2) (39, 
43–51), but only two concerned ATL causing species (39, 51). 
In all of them, protection was demonstrated to be associated 
with the induction of multifunctional T cells among other 
double producers or with TNF-α producing cells (either TNF-α 
single-positives or TNF-α/IL-2 and TNF-α/ IFN-γ double posi-
tive cells) (45–47, 51).
L. AMAZONENSIS veRSUS  
L. BRAZILIENSIS: DiFFeReNCeS ON 
QUALiTY OF iMMUNe ReSPONSe
It has already been reported that patients infected with parasites 
from the subgenus Viannia (as L. braziliensis) display higher T cell 
responses (evaluated by proliferation and IFN-γ production) to 
Leishmania crude antigens than L. amazonnsis-infected patients, 
and that L. amazonensis-infected patients also have stronger 
responses to L. braziliensis than to L. amazonensis antigens in vitro, 
before and after therapy (52).
Vaccine candidates formulated with L. braziliensis total extract 
have been tested against Canine VL (LBSap and LBSApSal) with 
promising results in phase I and II trials (53–55). LBSap induced 
both humoral and cellular immune responses against Leishmania 
infantum, with high levels of total IgG and its subtypes (IgG1 
and IgG2), expansion of circulating CD5+, CD4+, and CD8+ 
T lymphocytes as well as reduction of splenic parasite load (55).
One previous study designed to evaluate the quality of the Th1 
response induced by L. amazonensis and L. braziliensis promas-
tigotes extracts in PBMC from healed CL patients demonstrated 
that L. amazonensis response is associated with a low contribu-
tion of multifunctional T cells and a high number of IFN-γ 
single-positive effector cells, while L. braziliensis induces a Th1 
response with high proportion of multifunctional T cells and low 
proportion of IFN-γ single-positive cells (39). As IFN-γ single-
positive CD4+ T cells are short-lived, this can offer a possible 
explanation for the contrasting results observed in prophylaxis 
and immunotherapy studies with L. amazonensis whole-cell 
extract vaccine (Leishvacin®) (40, 56–58). The substantial amount 
of IFN-γ single-positive effector CD4+ T cells induced by this 
antigen may not be sufficient to induce long-term and good-
quality protection against infection, but could be effective when 
a rapid and transient Th1 response is needed, as in the case of 
immunotherapeutic interventions. In addition, the capacity of L. 
amazonensis promastigotes extract to induce IL-10 secretion (59, 
60), together with the generation of short-lived IFN-γ producing 
CD4+ T cells, could result in equilibrium between inflammatory 
and anti-inflammatory responses, allowing parasite killing and 
lesion resolution, as observed in the immunotherapeutic proto-
cols tested so far.
If we combine the information that mice healed from a pri-
mary infection with L. major present the highest proportion of 
multifunctional CD4+ T cells and protection after a homologous 
challenge (38), together with the results obtained in healed CL 
patients after stimulation with L. braziliensis and L. amazonensis 
promastigotes extracts (39), we can consider the possibility that 
patients healed from L. braziliensis infection should display better 
protection to reinfection than L. amazonensis healed patients.
It has never been reported that individuals that were infected 
with L. braziliensis or any other Leishmania specie are more 
susceptible to infection with L. amazonensis, but L. amazon-
ensis infection does not give protection against a subsequent 
FiGURe 1 | Demonstrative figure of the CD4 T cell response induce in 
PBMC cultures of one patient healed from localized cutaneous 
Leishmaniasis caused by L. braziliensis (Healed LCL) in comparison 
to the response induced in PBMC cultures obtained from one patient 
with diffuse cutaneous Leishmaniasis caused by L. amazonensis, 
during remission of symptoms (DCL). Cells were stimulated “in vitro” with 
total promastigotes extracts form L. braziliensis (LbAg) or L. amazonensis 
(LaAg) and stained with monoclonal antibodies to determine the frequency of 
CD4 T cells expressing IFN-γ, IL-2, and TNF-α by multiparametric flow 
cytometry. Combination gates were applied to determine the percentage of 
cells that were able to produce any combination of these three cytokines.  
To determine the contribution of each phenotype to the total Th1 immune 
response analyzed the results are represented in the pie charts comprising 
cells expressing all three cytokines (in red – IFN-γ+TNF-α+IL-2+), any two 
cytokines (in blue – IFN-γ+TNF-α+IL-2−, IFN-γ+TNF-α−IL-2+, and 
IFN-γ−TNF-α+IL-2+), or any one cytokine (in green – IFN-γ+TNF-α−IL-2−, 
IFN-γ−TNF-α+IL-2−, and IFN-γ−TNF-α−IL-2+). Detached is the contribution 
of the IFN-γ+TNF-α−IL-2− single-positive cells phenotype. Data showed in 
this figure are part of a published study (39) approved by the National Ethical 
Clearance Committee of Brazil (CONEP), as well as by the Ethical Committee 
for Human Research from IPEC/FIOCRUZ, all of which adhere to the 
principles laid out in the Declaration of Helsinki. Informed consent was 
obtained from all participants.
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challenge with L. braziliensis or other Leishmania specie from 
the subgenus Viannia. On the other hand, recovery from L. 
braziliensis infection confers resistance to homologous chal-
lenge as well as to infection with L. amazonensis or L. mexicana 
parasites (6, 7). Interestingly, cells from DCL patients infected 
with L. amazonensis are able to differentiate into multifunc-
tional T cells in vitro only after simulation with L. braziliensis 
promastigotes extract, while L. amazonensis stimulates high 
proportions of IFN-γ single-positive, terminal differentiated 
cells (Figure 1). This finding indicates that something intrinsic 
to L. amazonensis parasite antigens is responsible for the weak 
specific Th1 immune response observed during L. amazonensis 
infection (52, 61).
Even though parasites from the Viannia and Leishmania 
subgenera show highly conserved gene sequences with very few 
genes restricted to a given species (62–64), these similarities did 
not prevent different species from evolving some particularities 
related to the expression of virulence factors and the develop-
ment of particular evasion mechanisms. Recently, the genome of 
L. amazonensis was sequenced and compared with other human 
pathogenic Leishmania spp. indicating that L. amazonensis and 
L. mexicana share groups of amastin surface proteins unique 
to the genus that could be related to specific disease outcomes. 
Additionally, a hypothetical interactome model of host protein 
and secreted L. (L.) amazonensis proteins revealed a possible 
interaction between an L. (L.) amazonensis heat-shock protein 
and mammalian Toll-like receptor 9 (65).
The low generation of multifunctional T cells induced by L. 
amazonensis can be one more factor, or, and most likely, can be a 
consequence of many others already described in the literature, 
implicated with the susceptibility to this Leishmania specie 
(23, 59, 65–73).
CONCLUDiNG ReMARKS
Prophylactic immunization is accepted as the most efficient 
and low-cost/benefit alternative to control infectious diseases. 
An ideal vaccine against Leishmaniasis must have several 
attributes: (1) safety, (2) accessibility for populations at risk, (3) 
induce long-lasting CD4 and CD8 specific T cell response, (4) be 
effective against Leishmania species responsible for visceral and 
tegumentary forms, (5) stability at room temperature to be used 
in the field, and (6) have prophylactic and therapeutic potential 
(74). Although it is possible to fulfill the attributes related to cost/
benefit and safety, the development of a Leishmaniasis vaccine 
has proven a difficult goal to achieve. Not because of the discovery 
of candidate molecules, especially after the sequencing of the 
genome of different species of parasite, but rather because of the 
difficulties related to the still incomplete knowledge involving 
pathogenesis, the complex immune response needed for induc-
tion of protection, the lack of suitable experimental models, 
and the still fragmented knowledge about the development of 
immunological memory mechanisms.
Currently more than 30 Leishmania antigens have been or are 
being tested as candidate vaccines against visceral or tegumentary 
leishmaniasis. Many of them are very well conserved among dif-
ferent species of the parasite, but were not capable of inducing 
protection in clinical trials or are unable to protect against all 
species of the parasite. However, one study has demonstrated 
that heterologous protection is feasible, and associated with 
the presence of a “multifunctional Th1 response.” BALB/c mice 
immunized with a non-pathogenic Leishmania donovani parasite 
showed cross-protection against the challenge with L. major or L. 
braziliensis, and the immunization induced a long-term immune 
response characterized by high levels of multifunctional CD4 and 
CD8 T cells (48). Additionally, other authors observed a reduction 
in the frequency of parasitism in the bone marrow (54), as well 
as a reduction in splenic parasite loads (55) in dogs vaccinated 
against VL with LbSAP (a preparation of killed L. braziliensis 
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promastigotes together with saponin), after L. infantum infection, 
although multifunctionality were not evaluated in those studies.
A point that also needs to be emphasized is that in natural 
infection, all the Leishmania species are co-deposited into the 
skin together with the vector saliva, and that saliva contains 
factors able to modulate the immune response (75–77). Studies 
have demonstrated that pre-exposure of sand fly saliva lead to 
either disease exacerbation (78, 79) or protection (80–83) upon 
Leishmania infectious challenge. Carregaro et  al. (84) demon-
strated that different inocula of Lutzomyia longipalpis salivary 
gland extract could modify the cellular immune response, reflect-
ing in the pattern of susceptibility or resistance to L. braziliensis 
infection. It would be interesting to investigate whether a com-
bination of saliva proteins with Leishmania proteins or extracts 
can shape the immune responses against infection, altering the 
quality of the immune responses by increasing the frequencies 
of multifunctional T cells. Moreover, the use of components that 
participate in the initial phase of infection could improve vaccine 
efficiency at the earlier stages of infection.
Certainly, there is still a long road ahead of us until an ideal 
Leishmaniasis vaccine be developed, but it is also undoubtable 
that multiparametric flow cytometry gave us a powerful tool to 
better evaluate correlates of protection and the development of 
memory T cell responses after infection and immunization. Since 
the crude and synthetic antigens tested so far were not able to 
induce consistent protection against Leishmania infections, it 
may be time to turn away our efforts from finding new candidate 
molecules, and focus on evaluating new presentation approaches 
of existing conserved molecules, specially the design of safe new 
adjuvants, that could direct the T cell-specific response toward 
long-lasting memory and multifunctional T cell phenotypes.
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